Navigation Links
AMRI Announces Fourth Quarter 2012 Adjusted EPS of $0.17
Date:2/12/2013

ted States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development.

Forward-looking StatementsThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements include, but are not limited to, statements regarding the company's estimates of revenue, margins and earnings per share for the first quarter and full year 2013, statements made by the company's chief executive officer and chief financial officer, including statements under the caption "2013 Financial Guidance," statements regarding multi-year deals, statements regarding the partnering or out-licensing of the company's proprietary compounds, statements regarding the strength of the company's business and prospects, statements regarding the actions taken to reduce cost and improve operating performance, and statements concerning the company's momentum and long-term growth, including expected results for 2013. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to, the company's ability to attract and retain experienced scientists; trends in pharmaceutical and biotechnology companies' outsourcing of chemical research and development, including softness in these markets; sales of Allegra® and the impact of the "at-risk" launch of generic Allegra'/>"/>

SOURCE AMRI
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Quantum Materials Corporation Announces Non-Heavy Metal (Cadmium-Free) Tetrapod Quantum Dots
2. The In View Series Announces Plans for a New Series on 3D-Printing
3. Elsevier Announces the Launch of a New Journal: Journal of Forensic Radiology and Imaging
4. The In View series hosted by Larry King Announces plans for a series on Autoimmune Diseases
5. Murray Test Prep Announces the Launch of their Online Tutoring Services
6. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
7. MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results
8. China Cord Blood Corporation Announces Completion of Corporate Structure Consolidation
9. DNA Genotek Inc. Announces $10,000 GenoFIND™ Genomic Services Award
10. Spectrum Announces bioWorld Distribution Agreement
11. Life Technologies Announces Fourth Quarter and Fiscal 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... As the R&D sector becomes increasingly ... industry to deliver better products, faster. Collaborations between ... often means turning big ideas into reality, within ... with Sensidose AB and Recipharm, is one example ... market sooner. The partnership resulted in the development ...
(Date:5/21/2013)...  MacroGenics, Inc. today announced that an abstract ... Fc-modified chimeric monoclonal antibody (MAb), in patients with ... be presented at the 2013 Annual Meeting of ... Developmental Therapeutics - Immunotherapy Oral Abstract Session on ... The presentation will describe the results of a ...
(Date:5/21/2013)... May 21, 2013 Bed bugs have become ... My Cleaning Products, many turn to chemical-based pesticides for help ... health and environmental risks those solutions present, the company advised ... Bug Bully instead. , According to My Cleaning Products, ... they used to be. It shared that the pests have ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3
... , , , PRINCETON, ... Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced ... Officer, will present at the Rodman & Renshaw 11th Annual ... at 4:55 PM on Thursday, September 10, 2009 in the ...
... - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today that ... , , - Rodman & Renshaw 11th ... September 10, 2009 at 12:30 p.m. Eastern Time in the Fahnestock Salon, ... Hotel in New York City., - Thomas ...
... 2 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that ... Robert W. Baird & Co. 2009 Health Care Conference ... 2009 Health Care Conference in New York, New York, on September 9, 2009 ... Thomas Weisel Partners Healthcare Conference , Subsequently, Onyx will ...
Cached Biology Technology:DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference 2DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference 3DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference 4OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences 2Onyx Pharmaceuticals to Present at Two Upcoming Healthcare Conferences 2
(Date:5/21/2013)... infections occur in the body, stem cells in ... and differentiating into mature immune cells that can ... can deplete these cell populations, potentially leading to ... cancer. Now, a team of researchers led by ... has found that, in mouse models, the molecule ...
(Date:5/21/2013)... and health stores, phosphatidylserine is a natural food ... to improve cognition and slow memory loss, it,s ... impairment. Now a team headed by Prof. Gil ... University,s Department of Human Molecular Genetics ... functioning of genes involved in degenerative brain disorders, ...
(Date:5/21/2013)... of biomass experts , Where? Copenhagen, ... 03-07 June 2013 , Why? ... assessment, market and policy developments, manufacturing and installation, drawing ... benefiting from its 2013 edition from a record of ... countries, more than 240 plenary and oral presentations, more ...
Breaking Biology News(10 mins):Keeping stem cells strong 2Common food supplement fights degenerative brain disorders 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4
... the International Osteoporosis Foundation (IOF) in its 2009 publication, ... more than 50% of all osteoporotic fractures will occur ... there is a growing need for advanced clinical training ... epidemiology and specificities of osteoporosis and related bone disorders ...
... research could eventually lead to new approaches for controlling ... which are caused by trypanosomes carried by the bloodsucking ... reproduction evolved very early and is now ubiquitous in ... living organisms except bacteria). However, real evidence is ...
... of mucus associated with chronic bronchitis, according to a ... indicates cigarette smoke suppresses a protein that causes the ... bronchitis patients. The findings were published online ahead ... American Journal of Respiratory and Critical Care Medicine ...
Cached Biology News:Shining a light on trypanosome reproduction 2Cigarette smoking increases production of mucus in patients with bronchitis 2Cigarette smoking increases production of mucus in patients with bronchitis 3
... We deliversoluble protein or No Charge ... the best soluble protein results , 24 ... submitted , Powerful results on your most ... Optimization Service (SOS) uses proprietary tools and ...
... for proteomic scale kinase profiling, quantitative ... drug discovery research built on the ... synthesis platform. These microarrays are available ... Kinase Substrate - Peptide Microarray Service. ...
... immunological studies, vaccine development, and biosensor ... powerful Paraflo microfluidic on-chip synthesis platform. ... of our comprehensive Epitope Peptide Microarray ... Probe content is completely customer ...
... Introducing our Regulatory Edition of Molecular ... imaging systems for life science research and ... supports compliance with U.S. Food and Drug ... Part 11 Electronic Records; Electronic Signatures [21 ...
Biology Products: